ArticleWorld journal of clinical cases2025
Primary ileal squamous cell carcinoma: A case report and review of literature.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary ileal squamous cell carcinoma (PISCC) is a rare malignant tumor of the ileum. Its development is an exceptional phenomenon, as the ileal mucosa is lined exclusively by simple columnar epithelium, with no native squamous epithelium under physiological conditions. PISCC accounts for fewer than 0.001% of all intestinal malignancies. As of 2025, only 12 confirmed cases have been documented in the global literature, predominantly as isolated case reports. CASE SUMMARY: A 47-year-old female developed abdominal pain two years after chemotherapy for ovarian low-grade serous carcinoma (International Federation of Gynecology and Obstetrics stage IC1). Positron emission tomography/computed tomography showed localized thickening of the small intestinal wall in the right pelvic region with increased metabolic activity, suggesting implantation metastasis. The patient underwent partial ileal resection, intestinal anastomosis, appendectomy, omentectomy, and pericolic lymphadenectomy. Histopathological and immunohistochemical analyses confirmed a primary ileal low-grade squamous cell carcinoma. Postoperatively, the patient received intravenous doxorubicin plus carboplatin combined with anti-angiogenic targeted therapy. After six cycles, the regimen was changed to paclitaxel plus carboplatin with bevacizumab. Following five cycles, maintenance therapy with intravenous bevacizumab monotherapy was initiated, supplemented with adjunctive hepatoprotective agents. At the 30-month postoperative follow-up, the patient remained progression-free with no clinical or radiologic evidence of recurrence or distant metastasis.
conclusionAccurate diagnosis of PISCC requires integration of clinical history, systemic examination, histopathology, and immunohistochemical profiling to reduce misdiagnosis and missed diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.